, PhD Winthrop-University Hospital Atkinson, Mark, PhD University of Florida Bradshaw, Elizabeth, PhD Harvard Medical School Buckner, Jayne, MD Benaroya Research Institute at Virginia Mason Cambier, John, https://www.selleckchem.com/products/yap-tead-inhibitor-1-peptide-17.html PhD National Jewish Health Chaussable, Damien, PhD Benaroya Research Institute at Virginia Mason Clish, Clary, PhD Broad Institute of MIT and Harvard Eisenbarth, George, MD, PhD (teleconference) University of Colorado – Denver Faustman, Denise,

MD, PhD Harvard Medical School Greenbaum, Carla, MD (teleconference) Benaroya Research Institute at Virginia Mason Hendrikson, Ronald, PhD Memorial Sloan–Kettering Cancer Center Hessner, Marty, PhD Medical College of Wisconsin Kappler, John, PhD National Jewish Health Kent, Sally, PhD UMASS Medical College Kenyon, Norma, PhD University of Miami McKinney, Eoin, PhD University of Cambridge Miller, Steve, PhD Northwestern University Nepom, Jerry, MD, PhD – Chair Benaroya Research Institute at Virginia Mason Peakman, Mark, PhD.

King’s College London Phippard, Deborah, PhD Immune Tolerance Network Pugliese, Alberto, MD University of Miami Qiu, Ji, PhD Arizona State University Quintana, Fransisco J., PhD Harvard Medical School Roep, Bart, MD, PhD Leiden University Medical Center Sewell, Andy, PhD Cardiff University Ueno, Hideki, MD, PhD

Baylor Health von Herrath, Matthias, MD (teleconference) La Jolla Institute for Allergy and PD 332991 Immunology Waldron-Lynch, Frank, MD University of Cambridge None. “
“In recent years, the role of high mobility group box-1 (HMGB1) protein and its receptors in autoimmune diseases has received increasing attention. It has been documented that HMGB1 is associated with disease activity in patients with systemic lupus erythematosus (SLE). This study was undertaken to determine the potential role of receptor for advanced glycation end products (RAGE), one receptor for HMGB1, in the pathogenesis of SLE. Plasma levels of soluble RAGE (sRAGE) from 105 patients with clinical diagnosis of SLE Mirabegron and 43 healthy controls were determined by ELISA. Associations between sRAGE levels and clinical, laboratory characteristics were assessed. The data showed that plasma levels of sRAGE in patients with SLE were significantly lower than those in healthy controls (HC) (P = 0.003). Plasma sRAGE in patients receiving short-period treatment showed an immediate decrease compared with the untreated patients (P = 0.023). In contrast, plasma sRAGE in patients receiving long-period treatment were significantly increased compared to those with short-period treatment (P = 0.000) and comparable with those in HC (P = 0.305).